Philip R. Johnson

Animal models for acquired immunodeficiency syndrome.

T. Kindt, P. Johnson, S. Sawasdikosol, 1992, Advances in immunology.

Pathogenic diversity of simian immunodeficiency viruses.

P. Johnson, V. Hirsch, Vanessa M. Hirsch, 1994, Virus research.

Antibody-dependent enhancement of simian immunodeficiency virus (SIV) infection in vitro by plasma from SIV-infected rhesus macaques

D. Montefiori, P. Johnson, W. Robinson, 1990, Journal of virology.

Plasma viremia in macaques infected with simian immunodeficiency virus: plasma viral load early in infection predicts survival

N. Haigwood, J. Ranchalis, P. Johnson, 1997, Journal of virology.

Passive immune globulin therapy in the SIV/macaque model: early intervention can alter disease profile.

N. Haigwood, N. Letvin, J. Ranchalis, 1996, Immunology letters.

Novel Adeno-Associated Virus Vector Vaccine Restricts Replication of Simian Immunodeficiency Virus in Macaques

Mary J. Connell, Philip R. Johnson, Norman L. Letvin, 2005, Journal of Virology.

Multiple viral determinants contribute to pathogenicity of the acutely lethal simian immunodeficiency virus SIVsmmPBj variant

H. McClure, D. Anderson, P. Johnson, 1993, Journal of virology.

Molecular cloning of feline immunodeficiency virus.

R. Purcell, R. Olmsted, P. Johnson, 1989, Proceedings of the National Academy of Sciences of the United States of America.

Prolonged clinical latency and survival of macaques given a whole inactivated simian immunodeficiency virus vaccine.

D. Montefiori, P. Johnson, V. Hirsch, 1994, The Journal of infectious diseases.

Complement control proteins, CD46, CD55, and CD59, as common surface constituents of human and simian immunodeficiency viruses and possible targets for vaccine protection.

D. Montefiori, P. Johnson, V. Hirsch, 1994, Virology.